Panretin

RSS

Withdrawn

This medicine's authorisation has been withdrawn

alitretinoin
MedicineHumanWithdrawn

Dutch is available via eTranslation, the European Commission's machine translation service.

Translate to Dutch | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 1 January 2021, the European Commission withdrew the marketing authorisation for Panretin (SRD) (alitretinoin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Amdipharm Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Panretin (SRD) was granted marketing authorisation in the EU on 11 October 2000 for treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma (KS). The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2005. It was then granted unlimited validity in 2010. 

The European Public Assessment Report (EPAR) for Panretin (SRD) is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (706 kB - PDF)

Bekijk

español (ES) (636.14 kB - PDF)

Bekijk

čeština (CS) (690.6 kB - PDF)

Bekijk

dansk (DA) (635.31 kB - PDF)

Bekijk

Deutsch (DE) (635.69 kB - PDF)

Bekijk

eesti (ET) (634.79 kB - PDF)

Bekijk

ελληνικά (EL) (714.41 kB - PDF)

Bekijk

français (FR) (636.79 kB - PDF)

Bekijk

hrvatski (HR) (654.05 kB - PDF)

Bekijk

italiano (IT) (635.67 kB - PDF)

Bekijk

latviešu (LV) (697.88 kB - PDF)

Bekijk

lietuvių (LT) (657.7 kB - PDF)

Bekijk

magyar (HU) (685.93 kB - PDF)

Bekijk

Malti (MT) (690.48 kB - PDF)

Bekijk

Nederlands (NL) (636.07 kB - PDF)

Bekijk

polski (PL) (690.71 kB - PDF)

Bekijk

português (PT) (636.13 kB - PDF)

Bekijk

română (RO) (663.54 kB - PDF)

Bekijk

slovenčina (SK) (689.91 kB - PDF)

Bekijk

slovenščina (SL) (680.88 kB - PDF)

Bekijk

suomi (FI) (635.37 kB - PDF)

Bekijk

svenska (SV) (636.02 kB - PDF)

Bekijk

Product information

български (BG) (1.36 MB - PDF)

Bekijk

español (ES) (775.45 kB - PDF)

Bekijk

čeština (CS) (1.15 MB - PDF)

Bekijk

dansk (DA) (816.4 kB - PDF)

Bekijk

Deutsch (DE) (758.96 kB - PDF)

Bekijk

eesti (ET) (768.31 kB - PDF)

Bekijk

ελληνικά (EL) (1.34 MB - PDF)

Bekijk

français (FR) (780.97 kB - PDF)

Bekijk

hrvatski (HR) (781.51 kB - PDF)

Bekijk

italiano (IT) (773.44 kB - PDF)

Bekijk

latviešu (LV) (1.15 MB - PDF)

Bekijk

lietuvių (LT) (773.63 kB - PDF)

Bekijk

magyar (HU) (1.12 MB - PDF)

Bekijk

Malti (MT) (1.18 MB - PDF)

Bekijk

Nederlands (NL) (782.84 kB - PDF)

Bekijk

polski (PL) (1.15 MB - PDF)

Bekijk

português (PT) (781.79 kB - PDF)

Bekijk

română (RO) (781.34 kB - PDF)

Bekijk

slovenčina (SK) (1.14 MB - PDF)

Bekijk

slovenščina (SL) (1.12 MB - PDF)

Bekijk

suomi (FI) (771.46 kB - PDF)

Bekijk

svenska (SV) (774.04 kB - PDF)

Bekijk

Íslenska (IS) (780.49 kB - PDF)

Bekijk

norsk (NO) (772.79 kB - PDF)

Bekijk
Latest procedure affecting product information:IAIN/0045
24/01/2019
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (670.87 kB - PDF)

Bekijk

español (ES) (621.3 kB - PDF)

Bekijk

čeština (CS) (650.02 kB - PDF)

Bekijk

dansk (DA) (622.59 kB - PDF)

Bekijk

Deutsch (DE) (620.46 kB - PDF)

Bekijk

eesti (ET) (621.29 kB - PDF)

Bekijk

ελληνικά (EL) (661.55 kB - PDF)

Bekijk

français (FR) (620.86 kB - PDF)

Bekijk

italiano (IT) (619.92 kB - PDF)

Bekijk

latviešu (LV) (658.79 kB - PDF)

Bekijk

lietuvių (LT) (640.83 kB - PDF)

Bekijk

magyar (HU) (657.79 kB - PDF)

Bekijk

Malti (MT) (662.45 kB - PDF)

Bekijk

Nederlands (NL) (620.27 kB - PDF)

Bekijk

polski (PL) (660.55 kB - PDF)

Bekijk

português (PT) (621.46 kB - PDF)

Bekijk

română (RO) (637.34 kB - PDF)

Bekijk

slovenčina (SK) (650.02 kB - PDF)

Bekijk

slovenščina (SL) (645.35 kB - PDF)

Bekijk

suomi (FI) (619.4 kB - PDF)

Bekijk

svenska (SV) (628.43 kB - PDF)

Bekijk

Product details

Name of medicine
Panretin
Active substance
alitretinoin
International non-proprietary name (INN) or common name
alitretinoin
Therapeutic area (MeSH)
Sarcoma, Kaposi
Anatomical therapeutic chemical (ATC) code
L01XX22

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Panretin gel is indicated for the topical treatment of cutaneous lesions in patients with acquired-immune-deficiency-syndrome (AIDS)-related Kaposi's sarcoma (KS) when:

  • lesions are not ulcerated or lymphoedematous, and;
  • treatment of visceral KS is not required, and;
  • lesions are not responding to systemic antiretroviral therapy, and;
  • radiotherapy or chemotherapy are not appropriate.

Authorisation details

EMA product number
EMEA/H/C/000279
Marketing authorisation holder
Eisai GmbH

Eisai GmbH
Edmund-Rumpler-Strasse 3
60549 Frankfurt am Main
Germany

Marketing authorisation issued
11/10/2000
Revision
17

Assessment history

This page was last updated on

Share this page